Photo of Michael  Lanuti, MD

Michael Lanuti, MD

  • Director, Thoracic Oncology, Division of Thoracic Surgery

617-726-6751

Accepting New Patients

Request a patient consultation

Overview

Dr. Lanuti is a board certified Thoracic Surgeon with special interest in lung cancer research, new techniques for lung cancer staging, and minimally invasive lung surgery.

Departments

Thoracic Surgery

Surgery

Centers & Specialties

Cancer Center

Clinical Interests
  • Thoracic surgery
  • VATS / Minimally Invasive Thoracic Surgery
  • Lung cancer and lung cancer molecular screening
  • Navigation bronchoscopy of lung nodules
  • Radiofrequency Ablation of Lung Tumors
  • Lung nodules and ground glass opacities
  • Endobroncial ultrasound for lung cancer staging
  • Esophageal cancer
  • Mediastinal tumors (Thymoma, Schwannoma, Germ Cell Tumors)
  • Thymoma and surgical treatment of myasthenia gravis
  • Chest wall tumors
  • Palmar hyperhidrosis
  • Mesothelioma
  • Tracheal surgery
  • Interstitial lung disease
Medical Education
  • MD, University of Pennsylvania School of Medicine
  • Residency, Hospital of the University of Pennsylvania
  • Fellowship, Massachusetts General Hospital
Board Certifications
  • Surgery
  • Thoracic Surgery (Cardiothoracic Vascular Surgery)
Foreign Languages
  • Spanish
Locations
  • Boston: Massachusetts General Hospital
  • Newton: Newton-Wellesley Hospital
Existing Patients
Patient Gateway
Insurances Accepted
  • Aetna Health Inc.
  • AllWays Health (NHP) - ACD
  • AllWays Health (NHP) - PBO
  • Beech Street
  • Blue Cross Blue Shield - Blue Care 65
  • Blue Cross Blue Shield - Indemnity
  • Blue Cross Blue Shield - Managed Care
  • Blue Cross Blue Shield - Partners Plus
  • BMC HealthNet Mass Health MCO/ACO
  • Cigna (PAL #'s)
  • Commonwealth Care Alliance
  • Fallon Community HealthCare
  • Great-West Healthcare (formally One Health Plan)
  • Harvard Pilgrim Health Plan - ACD
  • Harvard Pilgrim Health Plan - PBO
  • Health Care Value Management (HCVM)
  • Humana/Choice Care PPO
  • MassHealth
  • Medicare
  • Medicare - ACD
  • OSW - Connecticut
  • OSW - Maine
  • OSW - New Hampshire
  • OSW - Rhode Island
  • OSW - Vermont
  • Private Health Care Systems (PHCS)
  • Railroad Medicare
  • Railroad Medicare - ACD
  • Senior Whole Health
  • TriCare
  • Tufts Health Plan
  • Unicare
  • United Healthcare (non-HMO) - ACD
  • United Healthcare (non-HMO) - PBO
  • Well Sense Pediatrics

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.

Patient Age Group
Adult and Pediatric
Provider Gender
Male

Biography

After receiving a Bachelor of Science in BioEngineering from the University of Pennsylvania, Dr. Lanuti received his M.D. degree from the University of Pennsylvania School of Medicine . He completed his internship and residency in Surgery at the Hospital of the University of Pennsylvania and a two year research fellowship in a Thoracic Oncology Laboratory focusing on gene therapy for lung cancer. He continued with sub-specialty training, and finished a Cardiothoracic Fellowship at the Massachusetts General Hospital. He was recruited in 2004 to the staff of the Division of Thoracic Surgery, and holds a parallel appointment as Associate Professor of Surgery at Harvard Medical School. He has been the Friedman-Lambert Scholar in Academic Thoracic Surgery at MGH/HMS since 2004.  He is the Director of Thoracic Oncology for the Division of Thoracic Surgery.  Clinical interests include minimally invasive surgery for lung cancer, complex airway tumors, mediastinal tumors, esophageal cancer, navigation bronchoscopy, and surgery for hyperhidrosis. 

Research & Publications

Research Summary

Dr. Lanuti spearheads translational research in a Thoracic Oncology Research Laboratory. The principle goals of the laboratory are to design novel therapeutics to treat lung and esophageal cancer that can be brought to clinical trials. A primary goal is the use of oncolytic viruses to target solid tumor. Some of these strategies include development of oncolytic viruses that help degrade tumor matrix. Ultimately, this translational effort will strive to bring treatment strategies from the laboratory bench to the bedside and back to the bench again for re-evaluation and improvement.

Another lab interest is molecular imaging of pulmonary fibrosis.  We have pioneered the first collagen-PET probe to be used in the quantitation of patients carrying a diagnosis of pulmonary fibrosis. This same technology will be used to better characterize radiation induced lung injury which may ultimately be used to help differentiate lung injury from tumor recurrence.  

Stage I non small cell lung cancer can still recur with a 25% chance of relapse despite complete resection.  Dr. Lanuti is investigating the role of driver mutations and gene signatures to stratify risk of recurrence in resected stage I lung adenocarcinoma. This work can contribute to adjuvant therapies for high risk resected stage I lung cancers.

The study of epidermal growth factor and its influence on biologic functions, particularly the proliferation and differentiation of epithelial tissues, has received tremendous attention. Dr. Lanuti has investigated molecular risk factors for esophageal adenocarcinoma and found an elevated risk associated with single nucleotide polymorphisms in the epidermal growth factor (EGF) gene.

Publications

View my most recent publications at PubMed

Recent Publications:

  • Costantino CL, Geller AD, Wright CD, Ott HC, Muniappan A, Mathisen DJ, Lanuti M.  Carinal surgery: A single-institution experience spanning 2 decades. J Thorac Cardiovasc Surg. 2018 Dec 15.
  • Geller, AD, Zheng H, Gaissert HA, Mathisen DJ, Muniappan A, Wright CD, Lanuti M.  Relative Incremental Cost of Postoperative Complications of Esophagectomy. Sem Thor Cardiovasc Surg. 2019 Summer;31(2):290-299.
  • Geller AD, Zheng H, Mathisen DJ, Wright CD, Lanuti M. Relative incremental costs of complications of lobectomy for stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2018 Apr;155(4):1804-1811.
  • Désogère P, Tapias LF, Hariri LP, Rotile N, Rietz TA, Probst CK, Blasi F, Day H, Elliot J, Mino-Kenudson M, Weinreb P, Violette SM, Tager AM, Lanuti M, Caravan P. Type I collagen-targeted PET probe for pulmonary fibrosis detection and staging in preclinical models. Science Trans Med. 2017 Apr 5;9(384).
  • Izar B, Sequist L, Lee M, Muzikansky A, Heist RS, Iafrate AJ, Dias-Santagata D, Mathisen DJ, Lanuti M. Impact of EGFR mutation status on outcomes in patients with resected stage I NSLC. Ann Thorac Surg. 2013 Sep;96(3):962-8.
  • Sharma A, Willers H, Digumarthy SR, Mathisen DJ, Shepard JO. Radiofrequency ablation for stage I non small cell lung cancer: management of loco-regional recurrence. Ann Thorac Surg, 2012 Mar;93(3):921-8.

News & Events

Contact

Division of Thoracic Surgery
55 Fruit Street
Founders 7
Boston, MA 02114-2696
Phone: 617-726-6751
Fax: 617-726-7667
Newton Wellesley Hospital
2000 Washington Street
Green Building
Newton, MA 02462-1650
Phone: 617-243-6447
Fax: 617-243-6449

Back to Top